West Pharmaceutical Services (WST) Other Accumulated Expenses (2009 - 2026)

West Pharmaceutical Services has disclosed Other Accumulated Expenses across 18 years of filings, most recently posting $202.2 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $202.2 million, up 8.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $202.2 million (up 8.48% YoY), and the FY2025 annual result was $175.3 million, down 6.85% from the prior year.
• Other Accumulated Expenses came in at $202.2 million for Q1 2026 at West Pharmaceutical Services, up from $175.3 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $222.8 million in Q2 2025 to a low of $2.3 million in Q3 2022.
• The 5-year median for Other Accumulated Expenses is $169.0 million (2024), against an average of $156.4 million.
• Across the five-year window, Other Accumulated Expenses slumped 97.98% in 2022 and soared 6695.83% in 2023, its largest moves.
• West Pharmaceutical Services' Other Accumulated Expenses stood at $183.8 million in 2022, then declined by 15.56% to $155.2 million in 2023, then gained by 21.26% to $188.2 million in 2024, then declined by 6.85% to $175.3 million in 2025, then increased by 15.35% to $202.2 million in 2026.
• The last three Other Accumulated Expenses figures came in at $202.2 million (Q1 2026), $175.3 million (Q4 2025), and $213.1 million (Q3 2025), per Business Quant data.